Elironrasib vs Sotorasib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: KRAS G12C · full Non-Small Cell Lung Cancer pipeline

Elironrasib

Developed by Revolution Medicines

Phase 1/2 in Non-Small Cell Lung Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2027 · NCT05462717 (registry estimate)

No aligned efficacy figure on record for this race.

Sotorasib

Marketed by Amgen and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04303780 · Phase 3 · completed

The 345 participants were randomized 1:1 to sotorasib or active-comparator docetaxel, but treatment assignment was not masked. The primary clinical endpoint, progression-free survival assessed by blinded independent central review, was met in favor of sotorasib, with median progression-free survival of 5.62 versus 4.47 months and a hazard ratio of 0.663 (p=0.002).

Next expected readout: November 2026 · NCT06249282 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68) (met)

Result source: NCT04303780

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointElironrasibSotorasib
PFS, median—Not reported5.6 vs 4.5vs Docetaxeln 171NCT04303780
2 other results
  • 7.7 200 mg BIW D1D2 + 960 mg QD · n 43 · Phase 2 · secondary NCT05054725
  • 2.6 140 mg BIW D1D2 + 960 mg QD · n 4 · Phase 2 · secondary NCT05054725
OS, median—Not reported12.4b200 mg BIW D1D2 + 960 mg QD · n 43NCT05054725
1 other result
  • 5.8 140 mg BIW D1D2 + 960 mg QD · n 4 · Phase 2 · secondary NCT05054725
ORR—Not reported—Trial running · NCT06497556
Duration of response, median—Not reported12.2b200 mg BIW D1D2 + 960 mg QD · n 11NCT05054725

PFS, median

Elironrasib
—Not reported
Sotorasib
5.6 vs 4.5vs Docetaxeln 171NCT04303780
2 other results
  • 7.7 200 mg BIW D1D2 + 960 mg QD · n 43 · Phase 2 · secondary NCT05054725
  • 2.6 140 mg BIW D1D2 + 960 mg QD · n 4 · Phase 2 · secondary NCT05054725

OS, median

Elironrasib
—Not reported
Sotorasib
12.4b200 mg BIW D1D2 + 960 mg QD · n 43NCT05054725
1 other result
  • 5.8 140 mg BIW D1D2 + 960 mg QD · n 4 · Phase 2 · secondary NCT05054725

ORR

Elironrasib
—Not reported
Sotorasib
—Trial running · NCT06497556

Duration of response, median

Elironrasib
—Not reported
Sotorasib
12.2b200 mg BIW D1D2 + 960 mg QD · n 11NCT05054725
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Elironrasib: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Elironrasib: 0 of 4 rows · Sotorasib: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSotorasib
Dropout rate
100%a
NCT04303780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 3 more results
—200 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
93%200 mg D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
100%140 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT04303780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 3 more results
—200 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
—200 mg D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
—140 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
53.8%a
NCT04303780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 3 more results
100%200 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
—200 mg D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
75%140 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
diarrhoea 41.4%
nausea 25.4%
decreased appetite 23.1%
NCT04303780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 2 more results
200 mg BIW D1D2 + 960 mg QD
diarrhoea 62.8%
alanine aminotransferase increased 46.5%
aspartate aminotransferase increased 44.2%
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
140 mg BIW D1D2 + 960 mg QD
alanine aminotransferase increased 75%
aspartate aminotransferase increased 75%
diarrhoea 75%
NCT05054725 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Sotorasib

PFS 5.62 vs 4.47 Docetaxel months
time to event · months
NCT04303780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
ORR 25.6% (n=43)200 mg BIW D1D2 + 960 mg QD
event count · % of participants
No placebo or comparator arm
NCT05054725 · Phase 2 · registry result, not featured evidence · combination · converted to % from 11 Participants as posted
show 1 more result
0% (n=4)*140 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
Duration of Response 12.19 months200 mg BIW D1D2 + 960 mg QD
time to event · months
No placebo or comparator arm
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
Disease Control 81% (n=42)200 mg BIW D1D2 + 960 mg QD
event count · % of participants
No placebo or comparator arm
NCT05054725 · Phase 2 · registry result, not featured evidence · combination · converted to % from 34 Participants as posted
show 1 more result
75% (n=4)*140 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
PFS 7.66 months200 mg BIW D1D2 + 960 mg QD
time to event · months
No placebo or comparator arm
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
2.64 months140 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
Overall Survival 12.45 months200 mg BIW D1D2 + 960 mg QD
time to event · months
No placebo or comparator arm
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
5.8 months140 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elironrasib's landscape · Sotorasib's landscape